Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.60 |
| ▸ | CCR2 | P41597 | 5/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.47 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5384939 | 0.97 | OPRM1 (0.59) | OPRM1OPRK1OPRL1CCR2ADRA1D | |
| SCHEMBL5387677 | 0.96 | OPRM1 (0.58) | OPRM1OPRK1OPRL1CCR2ADRA1D | |
| SCHEMBL5387561 | 0.93 | OPRM1 (0.62) | OPRM1OPRK1OPRL1CCR2ADRA1D | |
| SCHEMBL7090081 | 0.87 | CCR2 (0.53) | OPRM1OPRK1OPRL1CCR2ADRA1D | |
| SCHEMBL5396966 | 0.83 | OPRM1 (0.51) | OPRM1OPRK1OPRL1CCR2ADRA1D | |
| SCHEMBL5384995 | 0.83 | CCR2 (0.51) | CCR2ADRA1DHTR4 | |
| SCHEMBL5405266 | 0.81 | OPRM1 (0.51) | OPRM1OPRK1OPRL1CCR2ADRA1D | |
| SCHEMBL27598011 | 0.80 | OPRM1 (0.59) | OPRM1OPRK1OPRL1CCR2SLC6A4 | |
| SCHEMBL5493668 | 0.80 | OPRM1 (0.50) | OPRM1OPRK1OPRL1CCR2ADRA1D | |
| SCHEMBL5396156 | 0.80 | CCR2 (0.52) | CCR2ADRA1DSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100415737-C | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2008-09-03 | — | — | CN | disclosed |
| US-7276508-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2007-10-02 | — | — | US | disclosed |
| EP-1468996-B1 | Indole derivatives for the treatment of CNS disorders | LUNDBECK & CO AS H (DK) | 2007-09-26 | — | — | EP | disclosed |
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| EP-1294710-B1 | INDOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | LUNDBECK & CO AS H (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-6890916-B2 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2005-05-10 | — | — | US | disclosed |
| EP-1468996-A1 | Indole derivatives for the treatment of CNS disorders | H. Lundbeck A/S (DK) | 2004-10-20 | — | — | EP | disclosed |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | H. LUNDBECK A/S (DK) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176729-A1 | Indole derivatives useful for the treatment of CNS disorders | HTR4, TPH1, SLC6A3 | OPRM1 105/4885OPRK1 45/4885OPRL1 48/4885 |
| US-20030191133-A1 | Indole derivatives useful for the treatment of CNS disorders | TPH1, CHRM1, TPH2 | OPRM1 13/4885OPRK1 27/4885OPRL1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.